Effective Granisetron Hydrochloride Injection for Nausea and Vomiting
ProcurenetShort description
The Granisetron Hydrochloride Injection is a pharmaceutical-grade medication specifically designed to prevent and treat nausea and vomiting caused by radiotherapy and chemotherapy. Its primary active ingredient is 1 mg of Granisetron Hydrochloride per milliliter. It is a selective 5-HT3 receptor antagonist, is stored at room temperature, and has a shelf life of 24 months. Prepared and packaged in single-dose vials, it is administered intravenously. Please consult healthcare professionals for potential drug interactions and adverse reactions. Our injection is manufactured under Good Manufacturing Practices (GMP) and globally shipped.
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
Granisetron Hydrochloride Injection - A Proficient Solution for Nausea and Vomiting
Granisetron Hydrochloride Injection is a state-of-the-art pharmaceutical product that promises an effective response against nausea and vomiting, particularly induced by chemotherapy and radiotherapy. This treatment has been meticulously developed to ensure efficacy and patient safety, and it is produced to the highest pharmaceutical-grade standards.
Product Attributes:
- CAS Number: 107007-99-8
- Molecular Formula: C18H25ClN4O
- Molecular Weight: 348.88 g/mol
- IUPAC Name: 1-methyl-3-[(2R)-3,4-dihydro-1H-pyrrolo[3,4-b]quinolin-1-yl]propan-1-one hydrochloride
- Canonical SMILES: CC(C)N1CCN(CC1)CC2=NC=NC3=C2C=C(C=C3)N
- Boiling Point: 409.5±55.0 °C
- Flash Point: 201.0±31.5 °C
- Density: 1.1±0.1 g/cm3
- Solubility: Water, DMSO, Methanol
- Refractive Index: 1.657
Detailed Characteristics:
Granisetron Hydrochloride works by selectively blocking 5-HT3 receptors, which are believed to play a significant role in provoking nausea and vomiting during chemotherapy and radiotherapy. Through this mechanism of action, this injection can enhance patient comfort and possibly improve treatment adherence.
The drug has a long plasma half-life (9 hours), allowing for less frequent dosing and enhancing patient convenience. Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system; hence it has a low potential for drug-drug interactions.
Please note that while Granisetron Hydrochloride helps to control nausea and vomiting, it does not completely eliminate the risk. It is important to communicate any side effects, including excessive tiredness, stomach pain or swelling and constipation, to your healthcare provider.
This injection is contraindicated for patients known to have hypersensitivity to the drug or any of its components. The use of this drug in pregnant women should only be if clearly needed. The drug can be excreted in breast milk; therefore, decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
